skip to content
Primary navigation


Drug - Lotronex (alosetron hydrochloride) Tablets

October 2012

Therapeutic area - Irritable Bowel Syndrome (IBS), females only

Approval criteria

  • Female recipient 18 years of age or older - with severe diarrhea* - predominant irritable bowel syndrome (IBS) AND
  • Chronic IBS symptoms (generally lasting 6 months or longer) AND
  • The physician excluded anatomical or biochemical abnormalities of the gastrointestinal tract AND
  • Patient has not responded adequately to at least two drugs considered to be conventional therapy [e.g., dicyclomine, hyoscyamine, loperamide, diphenoxylate/atropine, fiber supplementation] for IBS AND
  • The physician is enrolled in the Lotronex Prescribing Program

*Accepted definition of severe IBS includes diarrhea and 1 or more of the following: 

  • Frequent and severe abdominal pain or discomfort
  • Frequent bowel urgency or fecal incontinence
  • Disability or restriction of daily activities due to IBS


MHCP Provider Call Center 651-431-2700 or 800-366-5411

back to top